Revive Therapeutics has entered into an LOI to acquire DiagnaMed Holdings Corp.'s intellectual property related to molecular hydrogen as a potential treatment for neurological and mental health disorders.

Target Information

Revive Therapeutics has announced a Letter of Intent (LOI) to acquire the complete rights to DiagnaMed Holdings Corp.'s intellectual property related to the application of molecular hydrogen as a potential treatment for neurological and mental health disorders. This acquisition will encompass all existing intellectual property stemming from DiagnaMed's research endeavors focusing on amyotrophic lateral sclerosis (ALS), as well as the Orphan Drug Designation (ODD) awarded for molecular hydrogen in ALS treatment.

The deal further includes a provisional patent application that delineates pharmaceutical methods and compositions for producing molecular hydrogen, aimed at addressing conditions such as dementia, Parkinson’s disease, traumatic brain injury, depression, anxiety, and PTSD.

Industry Overview in the United States

The mental health treatment sector in the United States is undergoing significant transformation, with an increasing focus on innovative therapies and approaches. The integration of psychedelic-assisted treatments, such as those involving psilocybin and MDMA, has gained traction as